MHRA paediatric investigation plan
Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain (Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain)
MHRA paediatric investigation plan MHRA-101495-PIP01-24 · Agreement
Key facts
| PIP number | MHRA-101495-PIP01-24 |
|---|---|
| Active substances | Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain, Split influenza virus, inactivated containing antigens equivalent to B-like strain |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of influenza disease |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Oct 28, 2024 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: